CHMFL-ABL/KIT-155
CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC50s of 46 nM and 75 nM, respectively), and it also presents significant inhibitory activities to BLK (IC50=81 nM), CSF1R (IC50=227 nM), DDR1 (IC50=116 nM), DDR2 (IC50=325 nM), LCK (IC50=12 nM) and PDGFRβ (IC50=80 nM) kinases. CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155) arrests cell cycle progression and induces apoptosis.
For research use only. We do not sell to patients.
- CAS No.: 2081093-21-0
- Formula: C33H38F3N5O3
- Molecular Weight:609.68
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
IC50: 46 nM (type II ABL), 75 nM (c-KIT), 81 nM (BLK), 227 nM (CSF1R), 116 nM (DDR1), 325 nM (DDR2), 12 nM (LCK), 80 nM (PDGFRβ)[1]
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BaF3 | GI50 |
>10 μM
Compound: 34
|
Growth inhibition of mouse BAF3 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
Growth inhibition of mouse BAF3 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| BaF3 | GI50 |
>10 μM
Compound: 34
|
Inhibition of BCR/ABL p210 fusion protein T315I mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
Inhibition of BCR/ABL p210 fusion protein T315I mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| BaF3 | GI50 |
0.012 μM
Compound: 34
|
Inhibition of Tel-fused PDGFR-alpha (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
Inhibition of Tel-fused PDGFR-alpha (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| BaF3 | GI50 |
0.014 μM
Compound: 34
|
Inhibition of Tel-fused PDGFR-beta (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
Inhibition of Tel-fused PDGFR-beta (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| BaF3 | GI50 |
0.033 μM
Compound: 34
|
Inhibition of human BCR/ABL p210 fusion protein expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
Inhibition of human BCR/ABL p210 fusion protein expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| BaF3 | GI50 |
0.035 μM
Compound: 34
|
Inhibition of Tel-fused VEGFR2 (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
Inhibition of Tel-fused VEGFR2 (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| BaF3 | GI50 |
0.078 μM
Compound: 34
|
Inhibition of Tel-fused c-KIT V559D mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
Inhibition of Tel-fused c-KIT V559D mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| BaF3 | GI50 |
0.124 μM
Compound: 34
|
Inhibition of Tel-fused c-KIT N822K mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
Inhibition of Tel-fused c-KIT N822K mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| BaF3 | GI50 |
0.149 μM
Compound: 34
|
Inhibition of Tel-fused c-KIT (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
Inhibition of Tel-fused c-KIT (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| BaF3 | GI50 |
0.162 μM
Compound: 34
|
Inhibition of Tel-fused CSF1R (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
Inhibition of Tel-fused CSF1R (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| BaF3 | GI50 |
0.221 μM
Compound: 34
|
Inhibition of Tel-fused c-KIT L576P mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
Inhibition of Tel-fused c-KIT L576P mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| BaF3 | GI50 |
0.27 μM
Compound: 34
|
Inhibition of BCR/ABL p210 fusion protein M356T mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
Inhibition of BCR/ABL p210 fusion protein M356T mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| BaF3 | GI50 |
0.386 μM
Compound: 34
|
Inhibition of Tel-fused LCK (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
Inhibition of Tel-fused LCK (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| BaF3 | GI50 |
0.49 μM
Compound: 34
|
Inhibition of BCR/ABL p210 fusion protein F317I mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
Inhibition of BCR/ABL p210 fusion protein F317I mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| BaF3 | GI50 |
0.658 μM
Compound: 34
|
Inhibition of Tel-fused BLK (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
Inhibition of Tel-fused BLK (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| BaF3 | GI50 |
0.67 μM
Compound: 34
|
Inhibition of BCR/ABL p210 fusion protein F317L mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
Inhibition of BCR/ABL p210 fusion protein F317L mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| BaF3 | GI50 |
0.98 μM
Compound: 34
|
Inhibition of BCR/ABL p210 fusion protein H369P mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
Inhibition of BCR/ABL p210 fusion protein H369P mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| BaF3 | GI50 |
1.01 μM
Compound: 34
|
Inhibition of Tel-fused c-KIT T670I/V559D double mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
Inhibition of Tel-fused c-KIT T670I/V559D double mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| BaF3 | GI50 |
1.67 μM
Compound: 34
|
Inhibition of BCR/ABL p210 fusion protein Y253H mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
Inhibition of BCR/ABL p210 fusion protein Y253H mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| BaF3 | GI50 |
1.84 μM
Compound: 34
|
Inhibition of Tel-fused c-KIT V654A mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
Inhibition of Tel-fused c-KIT V654A mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| BaF3 | GI50 |
1.85 μM
Compound: 34
|
Inhibition of Tel-fused c-KIT T670I mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
Inhibition of Tel-fused c-KIT T670I mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| BaF3 | GI50 |
2.87 μM
Compound: 34
|
Inhibition of Tel-fused c-KIT V559D/V654A double mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
Inhibition of Tel-fused c-KIT V559D/V654A double mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| BaF3 | GI50 |
5.06 μM
Compound: 34
|
Inhibition of Tel-fused c-KIT D816V mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
Inhibition of Tel-fused c-KIT D816V mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| BaF3 | GI50 |
6.08 μM
Compound: 34
|
Inhibition of BCR-fused DDR2 (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
Inhibition of BCR-fused DDR2 (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| BaF3 | GI50 |
9.77 μM
Compound: 34
|
Inhibition of Tel-fused DDR1 (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
Inhibition of Tel-fused DDR1 (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| CHO | GI50 |
>10 μM
Compound: 34
|
Antiproliferative activity against CHO cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
Antiproliferative activity against CHO cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| GIST882 | GI50 |
0.095 μM
Compound: 34
|
Antiproliferative activity against human GIST882 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
Antiproliferative activity against human GIST882 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| GISTT1 | GI50 |
0.023 μM
Compound: 34
|
Antiproliferative activity against human GISTT1 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
Antiproliferative activity against human GISTT1 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| HL-60 | GI50 |
7.34 μM
Compound: 34
|
Antiproliferative activity against human HL60 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
Antiproliferative activity against human HL60 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| K562 | EC50 |
<100 nM
Compound: 34
|
Inhibition of BCR/ABL p210 fusion protein autophosphorylation at Y245 in human K562 cells measured after 2 hrs by immunoblotting
Inhibition of BCR/ABL p210 fusion protein autophosphorylation at Y245 in human K562 cells measured after 2 hrs by immunoblotting
|
[PMID: 27966954] |
| K562 | GI50 |
0.027 μM
Compound: 34
|
Antiproliferative activity against human K562 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
Antiproliferative activity against human K562 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| KU812 cell line | GI50 |
0.056 μM
Compound: 34
|
Antiproliferative activity against human KU812 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
Antiproliferative activity against human KU812 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| MEG-01 | GI50 |
0.02 μM
Compound: 34
|
Antiproliferative activity against human MEG01 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
Antiproliferative activity against human MEG01 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| MOLM-14 | GI50 |
8.49 μM
Compound: 34
|
Antiproliferative activity against human MOLM14 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
Antiproliferative activity against human MOLM14 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| MV4-11 | GI50 |
8.14 μM
Compound: 34
|
Antiproliferative activity against human MV4-11 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
Antiproliferative activity against human MV4-11 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| Rec1 | GI50 |
3.47 μM
Compound: 34
|
Antiproliferative activity against human Rec1 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
Antiproliferative activity against human Rec1 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
| Sf9 | IC50 |
46 nM
Compound: 34
|
Inhibition of C-terminal His-tagged human ABL1 expressed in baculovirus infected SF9 cells using Tyr 02 peptide as substrate measured after 1 hr by FRET based Z'Lyte assay
Inhibition of C-terminal His-tagged human ABL1 expressed in baculovirus infected SF9 cells using Tyr 02 peptide as substrate measured after 1 hr by FRET based Z'Lyte assay
|
[PMID: 27966954] |
| U-937 | GI50 |
5.73 μM
Compound: 34
|
Antiproliferative activity against human U937 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
Antiproliferative activity against human U937 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
|
[PMID: 27966954] |
In Vitro
CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155) exhibits anti-proliferation activities in the BCR-ABL dependent CML cancer cell lines such as K562 (GI50: 0.027 µM), MEG-01 (GI50: 0.02 µM), and KU812 (GI50: 0.056 µM). It also potently inhibits the growth of c-KIT dependent GISTs cancer cell lines including GIST-T1 (GI50: 0.023 µM), GIST-882 (GI50: 0.095 µM) but not c-KIT independent GIST-48B (GI50: 3.96 µM) [1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2081093-21-0
-
Molecular Weight 609.68
-
Formula C33H38F3N5O3
-
SMILES
O=C(N1CCC(OC2=CC(NC(C3=CC=C(CN4CCN(C)CC4)C(C(F)(F)F)=C3)=O)=CC=C2C)CC1)C5=CC=C(C)N=C5
-
Synonyms
CHMFL-ABL-KIT-155
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
Purity & Documentation
References
[1]. Wang Q, et al. Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding. J Med Chem. 2017 Jan 12;60(1):273-289. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)